The PharmaNote is a quarterly publication of the University of Florida’s Family Practice Medical Group department of Pharmacy Services and departments of Community Health and Family Medicine and Pharmacy Practice. Originally a monthly publication, it debuted in October of 1985 with the primary objective of educating health care professionals about drug entities recently approved by the Food and Drug Administration. Currently, it is currently distributed nationwide to physicians and health care centers wiht an expansion upon its original goals.

The PharmaNote is written by Ambulatory Care Clinical Pharmacists, PGY1 Pharmacy Residents, and fourth year pharmacy students on their Ambulatory Care rotations. It provides readers with an in depth analysis of newly approved drug entities, updates on newly published guidelines, clinical applications of pharmacogenomics, clinical pearls for the use of over-the-counter medications within the ambulatory care setting and a review of how to use new medication administration devices.


current issue



September 2023, Quarter 3 2023

  • Sunlenca®: (lenacapavir): A First-in-Class Capsid Inhibitor Injected into the Market... pages 1-5
  • Clinical Pearl Prevention of HIV Transmission through PEP and PrEP... pages 5-7
  • OTC Corner: At Home HIV Tests...pages 8
  • Administrative Advice... Pages 9-12
  • Pharmacogenomics Corner: CYP2B6 Genotype-Guided Efavirenz Dosing... pages 12-14

June 2023, Quarter 2 2023

  • Turning the Tide with Tzield®: A New Drug Update... pages 1-5
  • Pharmacogenomics Corner: Updates to Dosing Recommendations for Sertraline... pages 5-7
  • Clinical Conundrums: Expanded CGM Coverage for Medicare & Medicaid Patients... pages 7-8
  • Make it Simple: Cinnamon for Blood Glucose Control...pages 8-9
  • Device Debrief: Educating Patients on Use of Freestyle Libre 3®... pages 9-11

March 2023, Quarter 1 2023

  • Statin Use in Pregnancy: A Clinician Update... pages 1-4
  • Pharmacogenomics Corner: Evaluating a Genetic Link to Statin-Induced Myalgias... pages 4-5
  • Clinical Conundrums: Insurance Coverage for PSCK9 6
  • Make it Simple: Evaluating OTC Fish Oil Products...pages 7-8
  • Device Debrief: Educating Patients on Use of Repatha®... page 8-9


December 2022

  • Nextstellis® (drospirenone/estetrol): The Next Big Thing in Birth Control

November 2022

  • Zegalogue® (dasiglucagon):A Sweet Medication to Treat Low Blood Sugar

October 2022

  • Quviviq® (daridorexant): Sweet Dreams in the Setting of Chronic Insomnia

September 2022

  • Using the PAK to Fight Back: Combating Helicobacter Pylori Infections with Novel Therapy
  • Personalized Medicine Corner— CYP2C19 Polymorphisms in Clopidogrel Use for Patients with Peripheral Artery Disease

August 2022

  • Overview of Current Evidence for Using Pharmacogenetic Testing to Guide Warfarin Initial Dose Selection

July 2022

  • Mounjaro® (Tirzepatide): A Sweeter Outlook for Patients with Type 2 Diabetes

June 2022

  • Kerendia® (finerenone): Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes

May 2022

  • How Smart is Technology?: Understanding the Role of Clinical Decision Support in the Primary Care Setting

April 2022

  • The Clot Thickens: Is There Enough Evidence to Use Direct Oral Anticoagulants in Antiphospholipid Syndrome?

March 2022

  • Qulipta® (Atogepant): Taking the Headache Out of Migraine Prevention

February 2022

  • Verquvo® (vericiguat): One-A-Day Keeps the Hospital Away
  • Personalized Medicine Corner�An Update to Medicare Coverage for Pharmacogenomics Testing

January 2022

  • Wegovy® (semaglutide): A Once-Weekly Weight Loss Injectable


December 2021

  • Review of the 2020 American Psychiatric Association Schizophrenia Treatment Guidelines

November 2021

  • Clostridioides is Not so Difficile with New Agents: A Review of the 2021 Update to the IDSA Clostridioides difficile Guidelines
  • Personalized Medicine Corner� Venlafaxine and CYP2D6

October 2021

  • Brexafemme® (ibrexafungerp): A Novel Drug to Knock Out Vulvovaginal Candidiasis

September 2021

  • Cabenuva® (cabotegravir/rilpivirine): Injecting New Life into Treatment of Human Immunodeficiency Virus

August 2021

  • Pondering Ponvory® (Ponesimod): Preparing for Multiple Sclerosis

July 2021

  • Gemtesa® (Vibegron): Freeing Patients from Overactive Bladder

June 2021

  • Zokinvy® (lonafarnib): Giving More Years of Life to the Old Children

May 2021

  • Klisyri® (tirbanibulin): Itching for an answer to actinic keratosis

April 2021

  • Imcivree® (setmelanotide): A Small Injection Leading to Big Weight Loss
  • Personalized Medicine Corner�Using the FDA Table of Pharmacogenetic Associations

March 2021

  • Primary Aldosteronism: An Underdiagnosed and Undertreated Cause of Hypertension

February 2021

  • Rukobia® (fostemsavir): Attempting to put the ART backing into antiretroviral therapy

January 2021

  • Veklury® (remdesivir): Will mediocrity suffice in a pandemic?
  • Personalized Medicine Corner� Pharmacogenomics: TPMP and NUDT15 in Inflammatory Bowel Disease


December 2020

  • Accrufer® (ferric maltol): A Novel Oral Iron Replacement Product for the Treatment of Iron Deficiency in Adults

November 2020

  • Dayvigo® (lemborexant): Putting unsafe insomnia treatment to bed

October 2020

  • Pizensy® (Lactitol) attempts to loosen the market in its treatment for Chronic Idiopathic Constipation
  • Personalized Medicine Corner— Pharmacogenomics: Proton Pump Inhibitors and CYP2C19

September 2020

  • Ongentys® (Opicapone): A Drug Lighting a New Path for Treatment of Parkinson�s Disease

August 2020

  • Ubrelvy® (ubrogepant): Adding to the Abortive Therapy Arsenal for Mi- graine Treatment

July 2020

  • Fetroja® (cefiderocol): A Modern Day Trojan Horse of Urinary Tract Infections
  • Personalized Medicine Corner: Pharmacogenetics of NSAIDs and CYP2C9

June 2020

  • Caplyta® (lumateperone): A Unique, New Therapy Option for the Treatment of Schizophrenia.
  • Editor�s corner: NDMA Impurities Continue

May 2020

  • Ervebo® (ebola zaire vaccine, live/rVSV?G- ZEBOV-GP ); Post-Epidemic Use Approval

April 2020

  • Nourianz® (istradefylline): A New Way to Switch Off Parkinson's
  • Personalized Medicine Corner: Using Pharmacogenetic Testing to Inform Atomoxetine Therapy

March 2020

  • Xcopri® (cenobamate); Attempts to Seize a Place in Therapy for Epilepsy

February 2020

  • Rybelsus® (oral semaglutide); An Easy Pill to Swallow in a Class of Injectables

January 2020

  • Evenity® (romosuzumab-aqqg); A Novel Agent for Osteoporosis in Postmenopausal Women at High Risk for Fracture
  • Personalized Medicine Corner: Pharmacogenetic Testing to InformCurrent and Future Drug Therapy


December 2019

  • Spravato® (Esketamine): An Old Drug With A New Indication For Major Depressive Disorder

November 2019

  • Sunosi® (Solriamfetol): A Novel Agent for Sleepiness in Narcolepsy or Obstructive Sleep Apnea
  • Editors Corner: Drug Impuri- ties in News Headlines

October 2019

  • Continuous Blood Glucose Monitoring: Is There a Proven Benefit?
  • Personalized Medicine Corner
  • Index of Volume 34

September 2019

  • Yupelri® (Revefenacin): The Only Nebulized Once-Daily Long-Acting Muscarinic Antagonist for Chronic Obstructive Pulmonary Disease

August 2019

  • Omadacycline: Cycling Past the Competition?

July 2019

  • Prucalopride: The Only Prokinetic Chronic Idiopathic Constipation Treatment in the United States
  • Using Pharmacogenetic Testing to Guide Antidepressant Selection: A Patient Case

June 2019

  • Baloxavir marboxil (XOFLUZA®) and the Management of Uncomplicated Influenza

May 2019

  • Ajovy™ (Fremanezumab): A New Preventive Treatment of Migraines in Adults
  • Emgality® (Galcanezumab): A New Treatment for Preventing Migraines

April 2019

  • Overview of the 2018 CHEST Guideline for Stroke Prevention in Patients with Atrial Fibrillation
  • Using Pharmacogenetics to Guide Proton Pump Inhibitor Dosing: A Patient Case

March 2019

  • Lucemyra® (Lofexidine): First Non-Opioid Approved for the Management of Acute Opioid Withdrawal

February 2019

  • Management of Stable COPD: Overview of Combination Inhalers LABA/LAMA and LABA/ICS
  • Editor�s Corner: 2018 Update to the AHA/ACC Cholesterol Management Guidelines

January 2019

  • Lokelma® (sodium zirconium cyclosilicate): A Novel Agent for Chronic Hyperkalemia Management
  • Personalized Medicine Corner: Incorporating Pharmacogenetics to Provide Drug Therapy Recommendations for Post-Operative Pain Management Following Total Knee Arthroplasty


December 2018

  • Aimovig®: A Novel Therapy for Preventive Treatment of Migraine

November 2018

  • Steglatro® (ertugliflozin): A New SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

October 2018

  • Andexanet Alfa: The First Factor Xa Inhibitor Reversal Agent
  • Personalized Medicine Corner
  • Index of Volume 33

September 2018

  • Semaglutide (Ozempic®): A New GLP-1 Agonist for Type 2 Diabetes Mellitus

August 2018

  • Latanoprostene Bunod (Vyzulta®): A New Ophthalmic Agent for Open-Angle Glaucoma and Ocular Hypertension
  • Secnidazole (Solosec®): A New Single-Dose Treatment for Bacterial Vaginosis

July 2018

  • Plecanatide (Trulance®): A New Guanylate Cyclase-C Agonist for CIC and IBS-C
  • Personalized Medicine: Genotype-Guided Opioid Prescribing

June 2018

  • Delafloxacin: A New Fluoro- quinolone for Acute Skin and Soft Tissue Infections

May 2018

  • Betrixaban: A New Oral Anticoagulant for Extended-Duration Thromboprophylaxis

April 2018

  • Shingrix®: A New Herpes Zoster Subunit Vaccine
  • Personalized Medicine Corner: Pharmacogenetics and Tamoxifen in the Treatment of Breast Cancer

March 2018

  • Abaloparatide (Tymlos®): A New Agent to Prevent Ver- tebral Fractures in Women with Osteoporosis

February 2018

  • Sarilumab (Kevzara®): A New Treatment for Rheu- matoid Arthritis

January 2018

  • Naldemidine (Symproic®): A New Treatment for Opioid-Induced Constipation
  • Personalized Medicine Corner: Patient Case� Pharmacogenetics in Primary Care

December 2017

  • Vitamin D Supplementation to Rechallenge Statin Therapy in Patients with Statin-Induced Myalgia

November 2017

  • Dupilumab (Dupixent®): A Novel Agent for Atopic Dermatitis
  • Editor�s Corner: Canagliflozin (Invokana®) Boxed Warning Update

October 2017

  • Combination GLP-1 Agonist and Basal Insulin for the Management of Type 2 Diabetes Mellitus
  • Personalized Medicine Corner
  • Index of Volume 32

September 2017

  • Management of Atopic Dermatitis with Synbiotics
  • Editor�s Corner: Rates of Hypoglycemia and Insulin Degludec: Updates from Clinical Trials

August 2017

  • Eucrisa® (crisaborole): A New Top- ical Agent for the Treatment of Atopic Dermatitis
  • Editor�s Corner: The VAST-D Ran- domized Clinical Trial

July 2017

  • New Evidence About an Old Drug: Role of Digoxin in Atrial Fibrillation
  • Once Versus Twice-Daily Dosing of Insulin Glargine: A Comprehensive Review of the Literature
  • Personalized Medicine Corner

June 2017

  • Single Maintenance and Reliever Therapy (SMART) for Asthma Control
  • A Review of Antiplatelet Therapy in Secondary Stroke Prophylaxis

May 2017

  • Lixisenatide (Adlyxin®): A New GLP-1 Agonist for Type 2 Diabetes Mellitus

April 2017

  • Pharmacologic Treatment of Orthostatic Hypotension
  • Personalized Medicine Corner

March 2017

  • Migraine Prophylaxis: A Review of Current and Future Therapies
  • Evolocumab (Repatha®): A New Agent for Treatment of Hyperlipidemia

February 2017

  • Lifitegrast (Xiidra®): A Novel Treatment for Dry Eye Disease

January 2017

  • Brivaracetam (Brivact®): A New Adjunctive Treatment for Partial- Onset Seizures
  • Personalized Medicine Corner

December 2016

  • Tiotropium/olodaterol (Stiolto®): A new fixed-dose combination thera- py for moderate-to-severe COPD

November 2016

  • Eluxadoline (Viberzi®): A Novel Agent for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

October 2016

  • Pseudoephedrine and Phenylephrine for Treatment of Nasal Congestion: A Comprehensive Review of Efficacy and Safety
  • Personalized Medicine Corner
  • Index of Volume 31

September 2016

  • Sumatriptan for Treatment of Migraines: Focus on Onzetra Xsail® (sumatriptan intranasal powder)

August 2016

  • Bexsero®: A New Vaccine Approved For Serogroup B Neisseria Meningitidis

July 2016

  • Intensive versus Standard Blood Pressure Goals for Treating Hypertnesion: A Review of Recent Landmark Trials
  • Personalized Medicine Corner

June 2016

  • Enstilar® (calcipotriene and betamethasone dipropionate): A new topical agent for the treatment of plaque psoriasis

May 2016

  • Pharmacologic Treatment of Gout Now and in the Future

April 2016

  • Idarucizumab (Praxbind®): A Novel Direct Thrombin Inhibitor Reversal Agent
  • Personalized Medicine Corner

March 2016

  • Umeclidinium (Incruse Ellipta®): A Long- Acting Muscarinic Antagonist for the Treatment of COPD
  • Indacaterol/glycopyrrolate (Utibron TM Neohaler®): A New Maintenance Treat- ment for COPD

February 2016

  • Insulin degludec (Tresiba®): Ultra-long basal insulin with less nocturnal hypoglycemia than glargine

January 2016

  • Ivabradine (Corlanor®): A novel agent to reduce hospitalization due to worsening heart failure
  • Personalized Medicine Corner

December 2015

  • Sacubitril/Valsartan (Entresto®): A New Dual Therapy Approved for Chronic Heart Failure

November 2015

  • Omega-3 Fatty Acids for Hypertriglyceridemia: Focus on Epanova®
  • Alirocumab (Praluent®), a PCSK9 Inhibitor for Reducing Cardiovascular Risk: Balancing Efficacy and Expenditures

October 2015

  • Nicotine Replacement Therapy (NRT) in Pregnancy
  • Index of Volume 30
  • Personalized Medicine Corner

September 2015

  • Fluticasone Furoate: A Once Daily Inhaled Corticosteroid for the Treatment of Asthma
  • Liraglutide (Saxenda®) Familiar Name, New use for Weight Management

August 2015

  • Olodaterol (Striverdi® Respimat®): A New Once-Daily Long-Acting ?- Agonist for the Treatment of COPD

July 2015

  • Efinaconazole (Jublia®): A New Topical Therapy for Toenail Onychomycosis
  • Personalized Medicine Corner

June 2015

  • Peramivir: A Novel Intravenous Neuraminidase Inhibitor for the Treatment of Influenza
  • Ceftolozane/tazobactam (Zerbaxa®) for Treatment of Complicated Urinary Tract Infections and Intra-abdominal Infections

May 2015

  • Edoxaban: A New Target Specific Oral Anticoagulant and It´s Place in a New and Growing Class
  • Dulaglutide: A New GLP-1 Receptor Agonist for the Treatment of Diabetes

April 2015

  • Oralair®, Ragwitek®, and Grastek®: Novel Approaches to Treating Pollen-Induced Allergic Rhinitis
  • Personalized Medicine Corner: Tramadol: Is toxicity risk affected by genotype?

March 2015

  • Empagliflozin (Jardiance®), A New SGLT2 Inhibitor to Treat Type 2 Diabetes: Third Time's A Charm?

February 2015

  • Oritavancin for Adults with Acute Bacterial Skin and Skin Structure Infections

January 2015

  • Oxycodone/naloxone (Targiniq ER®): A new option for chronic pain control
  • Personalized Medicine Corner: Opioids & Genetic Testing

December 2014

  • Suvorexant (Belsomra®): A New Treatment Option for Insomnia

November 2014

  • Afrezza® (Technosphere® Insulin Inhalation System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
  • Contrave® (naltrexone HCl/bupropion HCl): The Newest Combination Weight Loss Treatment

October 2014

  • Vorapaxar (Zontivity®) for Secondary Prevention of Thrombotic Cardiovascular Events
  • Index of Volume 29
  • PharmaNote® Throwback Vol. 1, No. 1
  • Personalized Medicine Corner

September 2014

  • Tedizolid Phosphate: A New Antimicrobial Agent Against MRSA

August 2014

  • Dalbavancin: A Novel Treatment for Acute Bacterial Skin and Skin- Structure Infections

July 2014

  • Albiglutide: A New Treatment Option for Type II Diabetes
  • Zohydro®: Extended-release Hydrocodone: A Review

June 2014

  • Dapagliflozin: A Review

May 2014

  • 2013 ACCF/AHA Guidelines for the Management of Heart Failure: Expanded Use of Natriuretic Peptides and Aldosterone Antagonists

April 2014

  • Linaclotide: A New Option for Irritable Bowel Syndrome with Constipation (IBSC)

March 2014

  • Vortioxetine (Brintellix®): A Review
  • Aptiom® (Eslicarbazepine acetate): A Review

February 2014

  • Duavee® (conjugated estrogens/ bazedoxifene): A review

January 2014

  • A Review of Non-hormonal Treatment Options for the Vasomotor Symptoms of Menopause with Emphasis on Brisdelle® (Paroxetine mesylate) and Serada® (Gabapentin ER)

December 2013

  • Anticoagulant Pharmacotherapy in Obese Patients

November 2013

  • Fluticasone Furoate/Vilanterol: A New Inhaled Corticosteroid/ Long-Acting Beta Agonist
  • Levomilnacipran: New SNRI for the Treatment of Major Depressive Disorder

October 2013

  • Osteoporosis Management Update: Comparing the 2010 and 2013 National Osteoporosis Foundation Guidelines
  • Index of Volume 28

September 2013

  • A Review of Aldosterone Antagonists in Diastolic Heart Failure
  • Tapentadol Extended-Release for Painful Diabetic Peripheral Neuropathy

August 2013

  • Aclidinium: A New Long-acting Anti-cholinergic Inhaler for COPD
  • Canagliflozin: A New Type 2 Diabetes Drug with a Novel Mechanism of Action

July 2013

  • A Review Of Intranasal Corticosteroids For The Treatment Of Allergic Rhinitis
  • Ospemifene: A SERM For The Treatment Of Postmenopausal Dyspareunia

June 2013

  • Perampanel: The First AMPA Receptor Antagonist
  • Alogliptin: A New Dipeptidyl- Peptidase-4 Inhibitor

May 2013

  • Off-Label Use Of Modafinil In Depression

April 2013

  • Guidelines For Atrial Fibrillation Management: Role Of The Affirm Trial
  • Vascepa: A New Fish Oil For Severe Hypertriglyceridemia

March 2013

  • Mirabegron: New Option For Treatment Of Overactive Bladder

February 2013

  • The New IDSA Recommendations For Acute Bacterial Rhinosinusitis: Empiric Antibiotic Therapy In Adults
  • Teriflunomide: A New Option In Multiple Sclerosis

January 2013

  • Deterrents To Narcotic Abuse: A Review Of Mechanisms And Clinical Application

December 2012

  • What’s New with Gabapentin?

November 2012

  • Rotigotine: Transdermal Dopamine Agonist For The Treatment Of Parkinson’s Disease

October 2012

  • Qnasl® (Beclomethasone Diproprionate)
  • Avanafil (Stendra®): The Newest Phosphodiesterase 5 Inhibitor

September 2012

  • Two New Drugs for Obesity: A Review

August 2012

  • Edarbyclor®: The First Antihypertensive Combination Drug Containing Chlorthalidone

July 2012

  • The Role of Exenatide in Diabetes: A Focus on Bydureon®

June 2012

  • Rivaroxaban: The First Fda Approved Oral Directed Factor Xa Inhibitor

May 2012

  • Vilazodone: A New Treatment For Major Depressive Disorder
  • An Update On The Treatment Of Gout: Focus On Febuxostat’s Role In  Therapy

April 2012

  • The Utility Of The CHADS2 Stroke Risk Scoring System For Atrial Fibrillation Patients

March 2012

  • Indacaterol Maleate: A New Once Daily Treatement Option for Chronic Obstructive Pulmonary Disease
  • Ranolazine: A New Treatment for Chronic Angina

February 2012

  • Are All Angiotensin Receptor Blockers Created Equal In Management Of Heart Failure?

January 2012

  • Apixaban: A New Oral Direct XA Inhibitor

December 2011

  • Ticagrelor: The First Oral, Reversible P2Y12 Receptor Antagonist For ACS

November 2011

  • An Update And Review Of Isoniazid In Tuberculosis

October 2011

  • Linagliptin: A New Option In The Treatment Of Type-Ii Diabetes
  • Ezogabine: A New Option In The Treatment Of Partial Seizures

September 2011

  • Roflumilast: A New PDE4 Inhibitor For COPD

August 2011

  • The Role Of Aspirin In The Primary Prevention Of Cardiovascular Disease In Diabetes

July 2011

  • Ceftaroline: A New Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureu

June 2011

  • Ulipristal Acetate (Ella®): A New Emergency Contraceptive
  • Azilsartan Medoxomil: An Overview Of Safety And Efficacy

May 2011

  • Optimizing The Dose Of Clopidogrel And Aspirin In Acute Coronary Syndrome

April 2011

  • Opioid-­Induced  Hyperalgesia

March 2011

  • Managing Hypothyroidism: A Review Of Thyroid Hormones

February 2011

  • Acute Otitis Media: A Review Of Pathogens, Increasing Bacterial Resistance And Treatment Considerations

January 2011

  • Dabigatran Etexilate: The First Fda- Approved Orally Available Direct Thrombin Inhibitor


December 2010

  • Helicobacter Pylori Positive Peptic Ulcer Disease: Antibiotic Resistance To First Line Therapy
  • Denosumab (Prolia®): Twice-Yearly Treatment For Osteoporosis

November 2010

  • Natazia®: A New Combination Oral Contraceptive
  • Jalyn® (Dutasteride/Tamsulosin): A New Option In BPH

October 2010

  • Adverse Skeletal Effects Of Bisphosphonates: A Review
  • Continuous Subcutaneous Insulin Infusion Vs. Multiple Daily Injections: A Review
  • Index For Volume 25 (Oct. 2009 - Sep 2010)

September 2010

  • Ustekinumab: A New Treatment Approach For Psoriasis

August 2010

  • Liraglutide: A Newly Approved Incretin Mimetic

  • Pitavastatin: A New Statin To Treat Hyperlipidemia

July 2010

  • Managing Diabetic Peripheral Neuropathy: A Review

June 2010

  • Telavancin: A Lipoglycopeptide For The Treatment Of Complicated Skin And Skin Structure Infections

  • Valturna® (Aliskiren/Valsartan): A New Combination Raas Inhibitor

May 2010

  • Treatment Of Chronic Hypertension During Pregnancy

April 2010

  • Depression In The Elderly: Drug Interactions And Tolerability For First- Line Pharmacotherapy

March 2010

  • Cycloset®: A Unique Approach To Treating Diabetes
  • Once Daily Aminoglycosides: A Review And Update

February 2010

  • Saxagliptin: A New “Gliptin” Approved For Type II Diabetes

January 2010

  • Review Of A New Anti-­Platelet Agent: Focus On Prasugrel


December 2009

  • Management Of Acne Vulgaris: A Review
  • Dronedarone: A New Option For Atrial Fibrillation

November 2009

  • An Overview Of Antimalarial Agents: Focus On Coartem®

October 2009

  • Pharmacokinetic Variability In Pregnancy And Proposed Labeling Changes
  • Index For Volume 24 (Oct. 2008 - Sep. 2009)

September 2009

  • Raas Inhibitors: Treatment And Prevention Of Atrial Fibrillation

August 2009

  • Symbyax®: The First Medication Approved For Treatment-Resistant Depression

July 2009

  • Milnacipran: A New Agent For Fibromyalgia

June 2009

  • Update On Statins: Focus On Unapproved Uses

May 2009

  • Managing Gestational Diabetes: A Review

March 2009

  • Zoledronic Acid: Once-Yearly Treatment For Osteoporosis

February 2009

  • The Management Of Neurodegenerative Symptoms In Huntington’s Disease

January 2009

  • Zygomycosis: An Update On Treatment Options


November 2008

  • The Role Of Probiotics In The Prevention Of Antibiotic-Associated Diarrhea

October 2008

  • An Update On Antiepileptic Agents: Focus On Second Generation Treatment Options
  • Index For Volume 23 (Oct. 2007—Sep. 2008)

September 2008

  • Diagnosis And Management Of Infectious Sinusitis

August 2008

  • Treximet® (Sumatriptan And Naproxen): The First Combination Triptan/Nsaid For Acute Migraine
  • Resistant Urinary Tract Infections

July 2008

  • Using Genetics To Drive Treatment: A Focus On Warfarin

June 2008

  • Desvenlafaxine (Pristiq®): A Selective Serotonin And Norepinephrine Reuptake Inhibitor
  • A Review Of Current Alzheimer’s Disease Pharmacotherapy

May 2008

  • Alternative Medicines Update: A Focus On The Most Common Products Your Patients Are Using

March 2008

  • New Drugs Approved In 2007

February 2008

  • Exforge®: A New Combination To Treat Hypertension
  • Maraviroc (Selzentry®): A Novel Antiretroviral

January 2008

  • Doripenem: The Newest Member Of The Carbapenem Family


December 2007

  • Budesonide And Formoterol (Symbicort®): A Review

November 2007

  • Rotigotine (Neupro®): The First Transdermal Dopamine Agonist For Parkinson’s Disease
  • Pharmacotherapy Of Onychomycosis: A Focus On Terbinafine

October 2007

  • A Review Of Acute Stress Ulcer Prophylaxis In The Intensive Care Unit
  • Index For Volume 22 (Oct. 2006—Sep. 2007)

September 2007

  • Lubiprostone (Amitiza®): The First Chloride Channel Activator For The Treatment Of Chronic Idiopathic Constipation
  • Alli®: An Over-The-Counter Orlistat

August 2007

  • Review Of Fibric Acid Derivatives In Primary And Secondary Prevention Of Coronary Heart Disease

July 2007

  • Tolvaptan: A New Approach To The Management Of Euvolemic And Hypervolemic Hyponatremia

June 2007

  • Rotateq®: A Pentavalent Human-Bovine Rotavirus Vaccine

May 2007

  • Posaconazole (Noxafil®): A New Broad Spectrum Triazole Antifungal

April 2007

  • Phenylephrine For Pseudoephedrine In Otc Cold Medicines: An Equal Exchange?
  • Overview Of Triptans In The Management Of Acute Migraine

March 2007

  • Aliskiren: A Direct Renin Inhibitor

February 2007

  • The Role Of Digoxin In Treating Systolic Heart Failure: An Update
  • Traditional Vs. Low-Dose Oral Contraceptives

January 2007

  • Migraine Prophylaxis


December 2006

  • Human Papillomavirus (Hpv) And Cervical Cancer: Implications Of Hpv Vaccines
  • Implanon®: A Review

November 2006

  • Darifenacin (Enablex®): A New Option For Treatment Of Overactive Bladder
  • Sitagliptin: A Dipeptidyl Peptidase Iv Inhibitor For Diabetes Mellitus Type 2

October 2006

  • Treatment Options For Acute Cough

September 2006

  • Pharmacotherapy Of Smoking Cessation: Focus On Varenicline
  • Rasagiline (Azilect®): A New Monoamine Oxidase B (Mao-B) Inhibitor For The Treatment Of Parkinson’s Disease.

August 2006

  • Phosphodiesterase-5 Inhibitors For Erectile Dysfunction
  • Rimonabant (Acomplia®): The First Endocannabinoid Receptor Antagonist For The Treatment Of Obesity

July 2006

  • Linezolid Vs. Vancomycin: An Evaluation In The Treatment Of Skin And Soft Tissue Infections And Hospital-Acquired Pneumonia Caused By Methicillin-Resistant S. Aureus (Mrsa)

June 2006

  • Ranolazine (Ranexa®): A Novel Agent For Angina

May 2006

  • The Use Of Herbal Supplements In The Treatment Of Hyperlipidemia

March 2006

  • Insulin Detemir: A New Tool To Fight Diabetes Mellitus
  • Pharmacotherapy Of Gout: An Update

February 2006

  • Community-Associated Methicillin-Resistant Staphylococcus Aureus (Mrsa): What You Should Know

January 2006

  • Byetta®: A New Pharmacological Option For Patients With Diabetes mellitus
  • Ropinirole: The First Fda-Approved Drug For Restless Legs Syndrome


November 2005

  • Update On Statins In ACS
  • Micafungin (Mycamine™): A New Antifungal Agent

October 2005

  • The Role Of Rozerem®, The First Melatonin Receptor Agonist, In The Treatment Of Insomnia
  • Index For Volume 20 (Oct. 2004—Sep. 2005)

September 2005

  • Treating Heart Failure In African Americans: Focus On Bidil®
  • Tygacil™: A New Broad-Spectrum Antibiotic

August 2005

  • Boniva®: A New Option For The Prevention And Treatment Of Osteoporosis

July 2005

  • Lunesta™: A New Nonbenzodiazepine For The Treatment Of Insomnia

June 2005

  • Campral®: A New Approach For The Treatment Of Alcohol Dependency
  • Overview Of Vasopressors And Inotropes In The ICU

May 2005

  • Xopenex®: The Beginning Of A New Trend In Pharmaceutics Or All Hype?

April 2005

  • Lyrica® For The Treatment Of Neuropathic Pain Disorders

March 2005

  • Vytorin™: Attacking Cholesterol With A Dual Mechanism

February 2005

  • Apidra®: A Rapid-Acting Insulin For The Treament Of Diabetes
  • Sanctura®: A New Alternative For Overactive Bladder

January 2005

  • Cymbalta®: A Dual Approach To Treating Depression

December 2004

  • Etoricoxib: A New Cox-2 Inhibitor

November 2004

  • Nesiritide: Use In Acute Decompensated Heart Failure

October 2004

  • Benzodiazepines For The Treatment Of Delirium Tremens
  • Index for Volume 18 October 2002 - September 2003

September 2004

  • TELITHROMYCIN (KETEK™) A New Antimicrobial Agent

August 2004

  • SYMBYAX® The First Fda-Approved Drug For The Treatment Of Bipolar Depression

February 2004

  • MEMANTINE (NAMENDA®) A New Option FOR Alzheimer’s Disease

January 2004

  • TADALAFIL (CIALIS®) Latest Option For The Treatment Of Erectile Dysfunction

December 2003

  • ETHINYL ESTRADIOL/ LEVONORGESTREL (SEASONALE®) A New Extended Cycle Oral Contraceptive

November 2003

  • Treating Uncomplicated Urinary Tract Infections In A Drug Resistant Era

October 2003

  • ROSUVASTATIN (CRESTOR®) A New Statin For The Treatment Of Dyslipidemia
  • Index for Volume 18 October 2002 - September 2003

September 2003

  • GEMIFLOXACIN (FACTIVE®) Dual-Targeting Fluoroquinolone
  • What practitioners should know about the new JNC 7 hypertension guidelines

August 2003

  • IBANDRONATE (BONIVIA™) A New Bisphosphonate For The Prevention And Treatment Of Osteoporosis
  • TERIPARATIDE (FORTEO®) Promising Treatment For Patients At Increased Risk For Osteoporosis-Related Fractures

July 2003

  • ADALIMUMAB (HUMIRA™) Novel Human Monoclonal Antibody For The Treatment Of Rheumatoid Arthritis
  • ATOMOXETINE (STRATTERA™) The First Non-Stimulant For The Treatment Of ADHD

June 2003

  • The Use of Leukotriene Receptor Antagonists to Treat Allergic Rhinitis

May 2003

  • Aripiprazole (ABilify®): A New Atypical Antipsychotic Drug
  • Olmesartan (Benicar™) A New Angiotensin II Receptor Antagonist

April 2003

  • Ezetimibe (Zetia®): A Novel Lipid-Lowering Agent
  • Dutasteride (Avodart™): A New 5a-Reductase Inhibitor

March 2003

  • EPLERENONE (INSPRA®): The First Selective Aldosterone Receptor Antagonist For The Treatment Of Hypertension

February 2003

  • Valdecoxib: A New cox-2-Specific Inhibitor
  • LEXAPRO™ A New Selective Serotonin Reuptake Inhibitor

Janurary 2003

  • Lyme Disease: Treatment & Prevention



December 2002

  • The Role of Serotonin Modulators in the Treatment of Irritable Bowel Syndrome
  • Update on The Guidelines for the Diagnosis and Management of Asthma

November 2002

  • Frovatriptan (Frova®): A new Triptan
  • Proton Pump Inhibitors in the Treatment of GERD: A Comparison

October 2002

  • An Update on the Screening Information and the Use of Leuprolide in Prostate
  • Index for Volume 17 October 2001 - September 2002

September 2002

  • HRT: Options for Menopausal Vasomotor Symptoms
  • Accutane® Update

August 2002

  • Advicor: The First Combination Antilipemic Agent
  • Insulin

June/July 2002

  • Protopic®: An Alternative to Topical Steroids in the Treatment of Atopic Dermatitis
  • Treating Community-Acquired Pneumonia In the Drug Resistant Era